Pacira BioSciences, Inc.
NASDAQ:PCRX
14.69 (USD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 674.978 | 666.823 | 541.533 | 420.83 | 421.026 | 337.277 | 286.63 | 276.371 | 248.997 | 197.668 | 85.551 | 39.084 | 15.689 | 14.562 | 15.006 | 13.925 |
| Cost of Revenue
| 241.957 | 199.295 | 140.255 | 117.328 | 106.712 | 86.845 | 87.915 | 110.104 | 71.837 | 77.44 | 54.772 | 32.139 | 16.739 | 12.276 | 12.301 | 17.463 |
| Gross Profit
| 433.021 | 467.528 | 401.278 | 303.502 | 314.314 | 250.432 | 198.715 | 166.267 | 177.16 | 120.228 | 30.779 | 6.945 | -1.05 | 2.286 | 2.705 | -3.538 |
| Gross Profit Ratio
| 0.642 | 0.701 | 0.741 | 0.721 | 0.747 | 0.743 | 0.693 | 0.602 | 0.711 | 0.608 | 0.36 | 0.178 | -0.067 | 0.157 | 0.18 | -0.254 |
| Reseach & Development Expenses
| 76.257 | 84.797 | 55.545 | 59.421 | 72.119 | 55.688 | 57.29 | 45.678 | 28.662 | 18.731 | 21.56 | 9.937 | 14.873 | 18.628 | 26.233 | 33.214 |
| General & Administrative Expenses
| 116.401 | 109.52 | 88.323 | 74.834 | 71.119 | 70.159 | 66.691 | 63.395 | 61.31 | 41.652 | 20.959 | 15.974 | 20.159 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 153.04 | 144.996 | 111.022 | 118.682 | 129.663 | 107.106 | 94.803 | 89.218 | 77.733 | 65.01 | 41.549 | 30.332 | 0 | 0 | 0 | 0 |
| SG&A
| 269.441 | 254.516 | 199.345 | 193.516 | 200.782 | 177.265 | 161.494 | 152.613 | 139.043 | 106.662 | 62.508 | 46.306 | 20.159 | 6.03 | 5.02 | 8.611 |
| Other Expenses
| -0.186 | 57.288 | 13.553 | 7.866 | 5.703 | -0.888 | 0.167 | -0.082 | -0.165 | -0.159 | -0.047 | -0.111 | 3.019 | 6.03 | 5.02 | 8.611 |
| Operating Expenses
| 345.698 | 396.601 | 268.443 | 260.803 | 278.604 | 232.953 | 218.784 | 198.291 | 167.705 | 125.393 | 84.068 | 56.243 | 35.032 | 24.658 | 31.253 | 41.825 |
| Operating Income
| 87.323 | 60.024 | 131.065 | 46.35 | 38.11 | 15.915 | -24.937 | -32.024 | 9.455 | -5.165 | -53.289 | -49.298 | -39.101 | -22.372 | -28.548 | -45.363 |
| Operating Income Ratio
| 0.129 | 0.09 | 0.242 | 0.11 | 0.091 | 0.047 | -0.087 | -0.116 | 0.038 | -0.026 | -0.623 | -1.261 | -2.492 | -1.536 | -1.902 | -3.258 |
| Total Other Income Expenses Net
| -25.622 | -46.722 | -74.661 | -26.261 | -48.858 | -2.452 | -8.433 | -0.082 | -0.288 | -0.482 | -4.068 | -1.451 | -2.721 | -0.034 | 0.367 | -0.224 |
| Income Before Tax
| 61.701 | 13.302 | 56.404 | 20.089 | -10.748 | -0.425 | -42.471 | -37.844 | 2.12 | -13.543 | -64.351 | -52.281 | -43.328 | -27.149 | -28.181 | -45.587 |
| Income Before Tax Ratio
| 0.091 | 0.02 | 0.104 | 0.048 | -0.026 | -0.001 | -0.148 | -0.137 | 0.009 | -0.069 | -0.752 | -1.338 | -2.762 | -1.864 | -1.878 | -3.274 |
| Income Tax Expense
| 19.746 | -2.607 | 14.424 | -125.434 | 0.268 | 0.046 | 0.14 | 0.105 | 0.264 | 0.173 | -0.442 | -3.952 | 7.246 | 4.777 | 3.159 | -3.501 |
| Net Income
| 41.955 | 15.909 | 41.98 | 145.523 | -11.016 | -0.471 | -42.611 | -37.949 | 1.856 | -13.716 | -63.909 | -52.281 | -43.328 | -27.149 | -31.707 | -41.862 |
| Net Income Ratio
| 0.062 | 0.024 | 0.078 | 0.346 | -0.026 | -0.001 | -0.149 | -0.137 | 0.007 | -0.069 | -0.747 | -1.338 | -2.762 | -1.864 | -2.113 | -3.006 |
| EPS
| 0.91 | 0.35 | 0.95 | 3.41 | -0.27 | -0.012 | -1.07 | -1.02 | 0.05 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| EPS Diluted
| 0.81 | 0.34 | 0.92 | 3.33 | -0.27 | -0.012 | -1.07 | -1.02 | 0.04 | -0.39 | -1.93 | -1.72 | -2.64 | -1.58 | -55.32 | -79.23 |
| EBITDA
| 162.897 | 121.469 | 144.618 | 66.863 | 43.813 | 23.088 | -15.824 | -30.783 | 9.968 | -4.942 | -47.33 | -49.134 | -29.047 | -18.086 | -24.483 | -41.308 |
| EBITDA Ratio
| 0.241 | 0.182 | 0.267 | 0.159 | 0.104 | 0.068 | -0.055 | -0.111 | 0.04 | -0.025 | -0.553 | -1.257 | -1.851 | -1.242 | -1.632 | -2.966 |